arrow
C

Christopher B. Cooper

global alliance for tb drug development
H指数:28
被引数:2,238

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Thioquinazolinones as Antituberculosis Agents Targeting Phosphopantetheinyl Transferase

噻唑并[3,2-a]喹唑啉酮类化合物作为靶向磷脂泛酰巯基乙胺转移酶的抗结核药物

2025-07-010
PRE
Redirecting raltitrexed from cancer cell thymidylate synthase to Mycobacterium tuberculosis phosphopantetheinyl transferase
2024-03-151
OAAI
Synthesis and structure-activity relationships for a new class of tetrahydronaphthalene amide inhibitors of Mycobacterium tuberculosis

新型结核分枝杆菌四氢萘酰胺类抑制剂的合成及构效关系

2022-02-019
OAAI
The Tuberculosis Drug Accelerator at year 10: what have we learned?
2021-07-0539
OAAI
Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility

抗利什曼/抗结核7-取代的2-硝基咪唑并恶嗪的新型接头变体提供了增强的溶解度

2021-01-2110
OA
Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity

支架变形以鉴定具有抗分枝杆菌活性的新型DprE1抑制剂

2019-09-2330
OAAI
3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel

贝达喹啉的3,5-二烷氧基吡啶类似物是有效的抗结核药,对hERG通道的抑制作用最小

2019-04-0186
OAAI